Premium
The number of circulating CD26 expressing cells is decreased in critical COVID ‐19 illness
Author(s) -
deKay Joanne T.,
May Teresa L.,
Riker Richard R.,
Rud Jonathan,
Gag David J.,
Sawyer Douglas B.,
Seder David B.,
Ryzhov Sergey
Publication year - 2023
Publication title -
cytometry part a
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.316
H-Index - 90
eISSN - 1552-4930
pISSN - 1552-4922
DOI - 10.1002/cyto.a.24547
Subject(s) - covid-19 , cd3 , immunology , t cell , medicine , peripheral blood , disease , immune system , cd8 , infectious disease (medical specialty)
We evaluated the number of CD26 expressing cells in peripheral blood of patients with COVID‐19 within 72 h of admission and on day 4 and day 7 after enrollment. The majority of CD26 expressing cells were presented by CD3 + CD4 + lymphocytes. A low number of CD26 expressing cells were found to be associated with critical‐severity COVID‐19 disease. Conversely, increasing numbers of CD26 expressing T cells over the first week of standard treatment was associated with good outcomes. Clinically, the number of circulating CD26 cells might be a marker of recovery or the therapeutic efficacy of anti‐COVID‐19 treatment. New therapies aimed at preserving and increasing the level of CD26 expressing T cells may prove useful in the treatment of COVID‐19 disease.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom